TABLE 1

DEC-HA treatment prevents the onset of diabetes

INS-HA/TCR-HATotal (n = 52)Diabetic (>200 μg/dl)*Nondiabetic (≤200 μg/dl)
DEC-HA treated161 (6)15 (94)
DEC-205 treated2112 (57)9 (43)§
Untreated156 (40)9 (60)
  • Data are n or n (%).

  • *

    * Diabetes was monitored by blood glucose measurement.

  • INS-HA/TCR-HA mice were injected with 0.5 μg DEC-HA conjugate or unconjugated DEC-205 antibody twice a week for 4 weeks, followed by injections once a week until the age of 12–16 weeks.

  • P ≤ 0.025, DEC-HA–treated vs. untreated mice;

  • §

    § P ≤0.01, DEC-HA–treated vs. DEC-205–treated mice; NS,

  • DEC-205–treated vs. untreated mice.